SARS-CoV-2 Total Antibody ELISA (DEIASL024)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Size
96T
Sample
Serum, plasma
Species Reactivity
Human
Intended Use
SARS-CoV-2 Total Antibody ELISA Kit is an enzyme-linked immunosorbent assay intend for qualitative detection of total antibodies to SARS-CoV-2 virus in human serum or plasma specimens.
Storage
The components of the kit will remain stable through the expiration date indicated on the label and package when stored between 2-8°C, do not freeze.
General Description
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, or 2019-nCoV) is an enveloped non-segmented positive-sense RNA virus. It is the cause of coronavirus disease 2019 (COVID-19), which is contagious in humans. The new coronavirus belongs to the beta coronavirus of the genus β, which has an envelope, the particles are round or oval, often polymorphic, and the diameter is 60-140nm. Its genetic characteristics are significantly different from SARSr-CoV and MERSr-CoV. Current research shows that it has more than 85% homology with bat SARS-like coronavirus (bat-SL- CoVZC45). In vitro isolation and culture, 2019-nCoV can be found in human respiratory epithelial cells in about 96 hours, while it takes about 6 days to isolate and culture in Vero E6 and Huh-7 cell lines. Based on current epidemiological investigations, the incubation period is generally 7 days, with a maximum of 14 days.
Main symptoms of infection include fever, fatigue, and dry cough. A few patients have symptoms such as nasal congestion, runny nose, and diarrhea. In severe cases, dyspnea occurs more than a week later. Besides, acute respiratory distress syndrome, septic shock, difficult to correct metabolic acidosis, and coagulation dysfunction develop rapidly. Current detection methods for new coronaviruses include nucleic acid detection and antibody detection. New coronavirus nucleic acids can be detected in throat swabs, sputum, lower respiratory tract secretions, and blood. Serum antibody testing helps confirm the infection status of a case.

Citations


Have you cited DEIASL024 in a publication? Let us know and earn a reward for your research.

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


SARS-CoV-2 and Health Care Worker Protection in Low-Risk Settings: a Review of Modes of Transmission and a Novel Airborne Model Involving Inhalable Particles

CLINICAL MICROBIOLOGY REVIEWS

Authors: Zhang, X. Sophie; Duchaine, Caroline

Since the beginning of the COVID-19 pandemic, there has been intense debate over SARS-CoV-2's mode of transmission and appropriate personal protective equipment for health care workers in low-risk settings. The objective of this review is to identify and appraise the available evidence (clinical trials and laboratory studies on masks and respirators, epidemiological studies, and air sampling studies), Clarify key concepts and necessary conditions for airborne transmission, and shed light on knowledge gaps in the field. We find that, except for aerosol-generating procedures, the overall data in support of airborne transmission-taken in its traditional definition (long-distance and respirable aerosols)-are weak, based predominantly on indirect and experimental rather than clinical or epidemiological evidence. Consequently, we propose a revised and broader definition of "airborne," going beyond the current droplet and aerosol dichotomy and involving short-range inhalable particles, supported by data targeting the nose as the main viral receptor site. This new model better explains clinical observations, especially in the context of close and prolonged contacts between health care workers and patients, and reconciles seemingly contradictory data in the SARS-CoV-2 literature. The model also carries important implications for personal protective equipment and environmental controls, such as ventilation, in health care settings. However, further studies, especially clinical trials, are needed to complete the picture.

Relationship between obesity and severe COVID-19 outcomes in patients with type 2 diabetes: Results from the CORONADO study

DIABETES OBESITY & METABOLISM

Authors: Smati, Sarra; Tramunt, Blandine; Wargny, Matthieu; Caussy, Cyrielle; Gaborit, Benedicte; Vatier, Camille; Verges, Bruno; Ancelle, Deborah; Amadou, Coralie; Bachir, Leila A.; Bourron, Olivier; Coffin-Boutreux, Christine; Barraud, Sara; Dorange, Anne; Fremy, Benedicte; Gautier, Jean-Francois; Germain, Natacha; Larger, Etienne; Laugier-Robiolle, Stephanie; Meyer, Laurent; Monier, Arnaud; Moura, Isabelle; Potier, Louis; Sabbah, Nadia; Seret-Begue, Dominique; Winiszewski, Patrice; Pichelin, Matthieu; Saulnier, Pierre-Jean; Hadjadj, Samy; Cariou, Bertrand; Gourdy, Pierre

Aim To assess the relationship between body mass index (BMI) classes and early COVID-19 prognosis in inpatients with type 2 diabetes (T2D). Methods From the CORONAvirus-SARS-CoV-2 and Diabetes Outcomes (CORONADO) study, we conducted an analysis in patients with T2D categorized by four BMI subgroups according to the World Health Organization classification. Clinical characteristics and COVID-19-related outcomes (i.e. intubation for mechanical ventilation [IMV], death and discharge by day 7 [D7]) were analysed according to BMI status. Results Among 1965 patients with T2D, 434 (22.1%) normal weight (18.5-24.9 kg/m(2), reference group), 726 (36.9%) overweight (25-29.9 kg/m(2)) and 805 (41.0%) obese subjects were analysed, including 491 (25.0%) with class I obesity (30-34.9 kg/m(2)) and 314 (16.0%) with class II/III obesity (>= 35 kg/m(2)). In a multivariable-adjusted model, the primary outcome (i.e. IMV and/or death by D7) was significantly associated with overweight (OR 1.65 [1.05-2.59]), class I (OR 1.93 [1.19-3.14]) and class II/III obesity (OR 1.98 [1.11-3.52]). After multivariable adjustment, primary outcome by D7 was significantly associated with obesity in patients aged younger than 75 years, while such an association was no longer found in those aged older than 75 years. Conclusions Overweight and obesity are associated with poor early prognosis in patients with T2D hospitalized for COVID-19. Importantly, the deleterious impact of obesity on COVID-19 prognosis was no longer observed in the elderly, highlighting the need for specific management in this population.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket